Fennec Pharmaceuticals Inc (FENC)
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company based in Research Triangle Park, North Carolina. The company focuses on PEDMARK, a sodium thiosulfate formulation developed to help prevent cisplatin-induced hearing loss in pediatric patients. It commercializes its product through regional pediatric oncology specialists and medical science liaisons. Fennec also has collaboration agreements with Tampa General Hospital Foundation, Inc. to evaluate the clinical utility of sodium thiosulfate injection in reducing ototoxicity risk in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment, as well as with Norgine Pharma UK Limited. Founded in 1996, the company was previously known as Adherex Technologies Inc. before adopting its current name in 2014.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-FENC
|
$12.62
|
14.7% Upside
|
Fair
|
$17.67
|
60.5% Upside
|
Bargain
|
Great
|
0.0%
|
November 5, 2026
|
9.0x
|
6.5x
|
386.1 M
|
341.3 M
|
0.0%
|
56.7%
|
4.4
|
62.8%
|
